Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin ...

By type of insulin, the long-acting insulin analogs segment accounted for the highest revenue-grossing segment in the global ...

a DB = double-blind, DM = diabetes mellitus, HbA 1c = glycosylated hemoglobin, MC = multicenter, NPH = isophane insulin human, NR = not recorded, OL = open-label, PG = parallel-group, R = randomized.

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...

The FDA approved its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin Tresiba (insulin degludec) got US approval late last year. [caption id ...

Short-acting insulins are mainly used in the bodybuilding community. This insulin enhances the muscle’s capability to absorb nutrients quickly after the workout. Intermediate and long-acting ...

Some diabetes patients in the U.S. have this year pushed back against the company's decision to stop selling its long-acting insulin Levemir, which is an analogue insulin. They say the move has ...

Crucially, the long-acting insulin was no worse than Tresiba when it came to rates of hypoglycaemia, when blood glucose levels dip too low, according to statistical comparisons between the drugs.

The global rapid acting insulin market was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027. The growth of the global rapid acting ...